Table 1.

Characteristics and comparison of 47 patients treated with taxane-based regimens and 44 patients treated with gemcitabine-based regimens

CharacteristicsNo. patients treated with taxane-based regimens (%)No. patients treated with gemcitabine-based regimens (%)P
Total no. patients4744
Gender
    Male39 (83)32 (72.7)0.24
    Female8 (17)12 (27.3)
Age, y
    Median60570.32
    Range41-7737-75
Histology
    Squamous cell carcinoma17 (36.2)15 (34.1)0.43*
    Adenocarcinoma23 (48.9)19 (43.2)
    Large cell carcinoma7 (14.9)10 (22.7)
Stage
    IIIB18 (38.3)13 (29.5)0.38
    IV29 (61.7)31 (70.5)
Weight loss
    <5%23 (48.9)16 (36.4)0.06
    >5%10 (21.3)18 (40.9)
    Missing data14 (29.8)10 (22.7)
Thoracic radiation for stage IIIB9 (50)4 (31)0.46
Cycle of chemotherapy
    Median (range)3 (1-6)3 (1-9)0.62
Chemotherapeutic regimen
    Carboplatin + paclitaxel29
    Carboplatin + gemcitabine5
    Cisplatin + paclitaxel18
    Cisplatin + gemcitabine37
    Gemcitabine alone2
  • * Comparison for squamous cell carcinoma histologic subtype.

  • Patients with weight loss <5% were compared with patients with weight loss >5% without taking into account the missing data.